phase I clinical study Caris Life Sciences, Essa Pharma Ink Liquid Biopsy Partnership for Prostate Cancer Trial Essa will use Caris' blood-based sequencing tests to assess the genetic profiles of mCRPC patients enrolled in a Phase I trial of the firm's investigational agent. FDA Approves Takeda's Exkivity With Thermo Fisher CDx for EGFR Exon20 Insertion-Positive NSCLC This is the first time the FDA has approved a drug specifically for NSCLC patients who harbor rare EGFR Exon20 insertion mutations. Burning Rock Biotech, Impact Therapeutics Partner on CDx for PARP Inhibitor Senaparib The NGS firm will work with Impact to develop companion diagnostics to select patients eligible for Impact's synthetic lethality drugs, beginning with senaparib. Hummingbird Bioscience, Novogene Partner to ID Cancer Patients With NRG1 Fusions in China Novogene will use next-generation sequencing to identify solid tumor patients eligible to enroll in clinical trials of Hummingbird's anti-HER3 agent, HMBD-001. MapKure, Personalis Partner to Screen Patients for BRAF Inhibitor Trial Personalis plans to develop a companion diagnostic to MapKure's BRAF inhibitor, BGB-3245, once biomarkers have been identified in the study. Feb 25, 2021 Kronos Bio Doses First Patient in CDK9 Inhibitor Trial With Tempus Performing Sequencing Dec 17, 2020 Merus, Sema4 Partner to Accelerate Enrollment in Zenocutuzumab Trial Nov 23, 2020 Novellus, Tempus Partner to Enroll Patients in BRAF Inhibitor Clinical Trial Program Oct 6, 2020 BostonGene Collaborates With Transgene, NEC Corporation on Trials of Bespoke Cancer Vaccine Aug 13, 2020 Strata, Mirati Therapeutics Partner on Tumor-Agnostic Clinical Trial of Novel KRAS G12C Inhibitor Feb 11, 2020 Natera, Elicio Therapeutics Partner on Phase I/II Pancreatic Cancer Study May 16, 2019 Roche Drug Shows Benefit in Pediatric Patients With Rare, Molecularly Defined Tumors Premium Feb 9, 2015 New Data Shows Higher Dose of Regulus HCV Drug Offers Better Viral Load Reductions Premium Jan 12, 2012 Quark Releases Positive Phase I Data on Ocular Neuroprotectant Premium Jun 9, 2011 Alnylam Presents Phase I Data at ASCO Showing Liver Cancer Drug Well Tolerated Premium Jan 6, 2011 Alnylam Releases Phase I Data Showing Liver Cancer Drug Reaches Target Tissue, Triggers RNAi Premium Dec 16, 2010 Alnylam Data Shows 'Predictable Correlation' of Clinical, Preclinical Findings on Cancer Drug Premium Mar 25, 2010 Calando, CalTech Researchers Publish Phase I Data on siRNA Cancer Drug Premium Breaking News UK Biobank Study Investigates Incomplete Penetrance of Mendelian Disease Variants MDxHealth Q3 Revenues Grow 23 Percent BioMérieux Q3 Revenues Increase 11 Percent, Firm Raises 2021 Guidance Germline Cancer Risk Genes May Hold Rhabdomyosarcoma Survival Clues, Study Suggests Danaher Q3 Revenues Rise 23 Percent, Beat Wall Street Estimates Horse Genetics Study Reveals Origins of Domestication, Use in Human Culture The Scan Guidelines for Ancient DNA Work More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature. And Cleared A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times. Suit Over Allegations The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director. Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.